Medicines List

Description

PlaquEx Combi contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products. It prevents the clumping of the platelets in the blood vessels and reduces the chances of blood clots forming.

Indications

PlaquEx Combi is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). PlaquEx Combi is a fixed-dose combination medicinal product for continuation of therapy in:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention;
– ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.

Subject to medical prescription.

Concentration and pharmaceutical form: 75 mg/75 mg hard capsules

Description

Ivabenor contains ivabradine. It mainly works by reducing the heart rate by a few beats per minute. This lowers the heart’s need for oxygen especially in situations when an angina attack is more likely to happen. Ivabenor thereby helps to control and reduce the number of angina attacks.

Indications

Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease in adults with normal sinus rhythm and heart rate ≥ 70 bpm.
Ivabradine is indicated:
– in adults unable to tolerate or with a contraindication to the use of beta-blockers;
– in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure II to IV class (according to NYHA classification) with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg, 7.5 mg film-coated tablets

Description

Coolsart is a combination of an angiotensin II receptor antagonist with olmesartan medoxomil and a thiazide diuretic – hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect which reduces blood pressure to a greater degree than either component alone.

Indications

Coolsart 20 mg/12.5 mg film-coated tablets
– treatment of essential hypertension;
– olmesartan medoxomil/hydrochlorothiazide 20 mg/12.5 mg fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil alone.

Coolsart 40 mg/12.5 mg film-coated tablets
– treatment of essential hypertension;
– olmesartan/hydrochlorothiazide 40 mg/12.5 mg fixed-dose combinations is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil 40 mg alone.

Subject to medical prescription.

Concentration and pharmaceutical form: 20 mg/12.5 mg; 40 mg/12.5 mg film-coated tablets

Description

Bilamcar combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, candesartan cilexetil and a dihydropyridinic calcium channel blocker, amlodipine. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.

Indications

Bilamcar is indicated for treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is already adequately controlled with the individual components given concurrently at the same dose levels as in the fixed combination, but as separate medicines.

Subject to medical prescription.

Concentration and pharmaceutical form: 8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, 16 mg/10 mg hard capsules